|
| Tuesday, August 29, 2023 |
|
|
Malaysian Genomics Unveils Strategic Advances in Biopharmaceuticals |
| Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, recorded a revenue of RM2.23 million for the 4th quarter ended 30 June 2023. This represents a decrease from RM6.33 million in the corresponding quarter of the preceding year, owing to a deliberate pivot from vaccines to cell and gene therapy products, focusing more on genetic screening initiatives. more info >> |
|
| Monday, May 15, 2023 |
|
|
Malaysian Genomics Inks Agreement in Expansion to Bangladesh |
| Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, today announced a strategic cooperation agreement (SCA) with Toticell Limited for the distribution of the Group's products in Bangladesh. more info >> |
|
| Monday, February 27, 2023 |
|
|
Malaysian Genomics to Boost Play on the Football Pitch |
| Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, is collaborating with KL City FC Sdn Bhd (KLCFC), the manager of the KL City FC football club, on the deployment of the Group's genetic screening tests for peak athletic performance. more info >> |
|
| Friday, February 24, 2023 |
|
|
Malaysian Genomics Pivots to Biopharmaceuticals for Growth |
| Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, today announced that the Group recorded a revenue of RM1.64 million for the second quarter ended 31 December 2022 (2Q 2023). This amount is down from RM7.63 million in 2Q 2022, as the Group moved its focus from vaccines to biopharmaceuticals. more info >> |
|
|
Malaysian Genomics to Collaborate on Cannabinoid R&D |
| Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, today announced that the Group has entered into a strategic collaboration with Kensana Health Canada and MAHSA University for the research and development (R&D) of phytopharmaceutical and biotechnology products that can lead to commercialisation. more info >> |
|
| Wednesday, February 22, 2023 |
|
|
Malaysian Genomics to Offer World's First DNA-Driven Fertility Test |
| Malaysian Genomics Resource Centre Bhd, a leading genomics and biopharmaceutical specialist, today announced that the Group has signed a strategic collaboration agreement with Divine Genes Sdn Bhd to collaborate on business opportunities in relation to the improvement and international distribution of genetic tests for reproductive health. more info >> |
|
| Monday, January 9, 2023 |
|
|
Malaysian Genomics Explores R&D Collaboration with SIRIM |
| Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to announce a strategic cooperation with SIRIM Berhad, to explore the commercialisation of joint research and development (R&D) projects in the medical and biotechnology fields. more info >> |
|
| Wednesday, November 23, 2022 |
|
|
Malaysian Genomics Sees Rise in Profit Margins for 1Q |
| Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, today reported a revenue of RM3.81 million for the first quarter ended 30 September 2022 (1Q 2023) versus a revenue of RM9.32 million in 1Q 2022, as the Group refocuses on immunotherapy and cell therapies under the biopharmaceutical business and pushes for organic growth of its genetic screening business. more info >> |
|
| Wednesday, October 26, 2022 |
|
|
Malaysian Genomics Signs Strategic Collaboration Agreement for Expansion in the UAE |
| Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, today announced the signing of a Strategic Collaboration Agreement (SCA) outlining partnerships to market and distribute the Group's Dtect(R) range of genetic screening services in the United Arab Emirates (UAE). more info >> |
|
| Wednesday, October 12, 2022 |
|
|
Malaysian Genomics Signs Agreement with National Institutes of Health to Explore Research Opportunities |
| MGRC Therapeutics Sdn Bhd (MGRC-T), a wholly-owned subsidiary of Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, has entered into a cooperation agreement with the National Institutes of Health, Malaysia (NIH), providing a framework for collaboration between the two parties in medical research pertaining to genomics and biopharmaceuticals. more info >> |
|
|
|
|
